Das Medizinportal


Schwerpunkt: Ovarialkarzinom - Die Chirurgie des Ovarialkarzinoms

Dr. Sonia Prader (ab Seite 10)

  1. Robert Koch Institut, Krebs in Deutschland, 2015
  2. Prat et al., Staging classification for cancer oft he ovary, follopian tube and peritoneum. Int J Gynaecol Obstet 2014;124:1-5
  3. du Bois et al., Das Qualitässicherungsprogramm der Kommission Ovar der AGO (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2011, Zentralbl Gynaekol 2005; 127: 9-17 
  4. Harter et al., Prospective validation study of a predictive score for operability of recurrent ovarina cancer: the Multicenter Intergroup Study DESKTOP II. A project oft the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011 Feb;21(2):289-95
  5. Paulsen et al., Improved  5-Year disease free survival fo FIGO stage I epithelail ovarian cancer patients without tumor rupture during surgery. Gynecol Oncol 2011;122(1):83-8
  6. Vergote et al., Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarina carcinoma. Lancet 2011;357(9251):176-82
  7. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Juni 2013 AWMF-Registernummer 032/035 OL
  8. Ataseven et al., Prognistic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer. Ann Surg Oncol. 2016 Jul (Epub ahead of print)
  9. Grabowski et al., Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol 2012;21(1):31-5
  10. Timmers et al., Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer 2010;46(5):880-4
  11. Trimbos et al., Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010;102(13):982-7
  12. du Bois et al., Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospecively randomized phase III multicenter trials. J Clin Oncol 2010;28(10):1733-9
  13. Harter et al., Impact of a structured quality management program on surgical outcome in primary advance ovarian cancer. Gynecol Oncol 2011;121(3):615-9
  14. Hoffman et al., Colon resection for ovarian cancer: Intraoperative decisions. Gynecol Oncol 2008;111(2 Suppl):56-65
  15. Kommoss et al., Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol 2010;17(1):279-86
  16. Peiretti et al., Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A mulit-center analysis of surgical and oncological outcomes. Gyecol Oncol 2012;126(2):220-3
  17. Schneider et al., Operative Therapie des primären Ovarialkarzinoms. Der Gynäkologe 2013;46 (8): 536-540
  18. Aletti et al., Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 2006;195(6):1862-8
  19. Chan et al., The potential therapuetic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 2007;96(12):1817-22
  20. Panici et al., Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advance ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97(8):560-6
  21. Heitz et al., Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol 2016;141(2):264-70
  22. Kehoe et al., Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trila. Lancet 2015;pii:S0140-6736(14)62223-6
  23. Vergote et al., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943-5
  24. Vergote du Bois et al., Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol 2013;128(1):6-11
  25. Kehlet et al., Multimodal approach to control postoperative pathophysiology and rehabilitation, Br J Anaesth 78 (1997) 606-617 
  26. Lidder et al., A randomized placebo controlled trial of preoperative carbohydrate drings and early postoperative nutritional supplement drinks in colorectal surgery. Colorectal Dis 2013;15(6):737-745
  27. Myriokefalitaki et al., Implementation of enhanced recovery after surgery (ERAS) in gynaecological oncology. Arch Gynecol Obstet 2016; 294:137-143
  28. Miralpeix et al., A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs. Gynecol Oncol 2016;141(2):371-8
  29. Ataseven et al., The revised 2014 FIGO staging system for epithelial ovarian cancer: is a subclassification into FIGO stage IVA and IVB justified? Gynecol Oncol 2016;142: 243-247
  30. du Bois et al., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux pour les Etudes des cancers de l’Ovaire (GINECO), Cancer 2009, 115: 1234-1244
  31. Bentivegna et al., Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Annals of Oncology 2016, Aug 8. (Epub ahead of print)
  32. Nelson et al., Guidelines for postoperative Care in Gynecologic/oncology surgery: Enhanced Recovery After Surgera (ERAS®) Society recommendations--Part II Gynecol Oncol. 2016 Feb;140(2):323-32. 
  33. Nelson et al., Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--Part I. Gynecol Oncol. 2016 Feb;140(2):313-22. 

Schwerpunkt: Ovarialkarzinom - Die medikamentöse Primärtherapie des Ovarialkarzinoms

Prof. Dr. Barbara Schmalfeldt (ab Seite 18)

  1. Grabowski JP, Harter P, Heitz F, Pujade Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A. Operability and chemotherapy responisveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group Metadatabase. Gynecol Oncol 2016, 140 (3):457-462
  2. du Bois, A., J. Rochon, C. Lamparter, J. Pfisterer für die AGO-Organkommission Ovar (2005) Ovarialkarzinom –Versorgungsstruktur und -qualität in Deutschland 2001–2004. Der Frauenarzt. 46(7): p. 560-567
  3. S3- Leitlinie „Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (AWMF-Register-Nummer 031-035OL) www.leitlinienprogramm-onkologie.de S3Leitlinie 
  4. Winter-Roach, B.A., H.C. Kitchener, and H.O. Dickinson, Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev, 2009(1): p. CD004706.
  5. Bell, J., et al., Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 2006. 102(3): p. 432-9.
  6. Chan, J.K., et al., The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 116(3): p. 301-6.
  7. Burger RA, Brady m, Bookman M, Fleming G, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer M, Liang SX, for the Gynecologic Oncology Group (2011). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 365:2473-2483. 
  8. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauriane E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MKB, Oza AM for the ICON7 Investigators (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 365:2484-96. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med. 363:943-53.
  9. Katsumata, N., et al., Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet, 2009. 374(9698): p. 1331-8.
  10. Armstrong, D.K., et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 2006. 354(1): p. 34-43.
  11. du Bois, A., Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 115(6): p. 1234-44.

Pädiatrische Onkologie - ein Überblick

Prof. Dr. Angelika Eggert (ab Seite 48)

  1. Kaatsch P, Spix C. German Childhood Cancer Registry - Annual Report 2015 (1980-2014). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University Mainz. www.kinderkrebsregister.de/dkkr/ergebnisse/jahresbericht.html 
  2. Eggert, A. Aktuelle Entwicklungen der pädiatrischen Onkologie – Neue Therapieoptionen, Versorgungskonzepte und Nachsorge. Klinikarzt 2015; 44(12): 635-642
  3. DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. ec.europa.eu/health/human-use/clinical-trials/directive/index_en.htm
  4. REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. ec.europa.eu/health/human-use/clinical-trials/regulation/index_en.htm
  5. Richtlinie über Maßnahmen zur Qualitätssicherung für die stationäre Versorgung von Kindern und Jugendlichen mit hämato-onkologischen Krankheiten gemäß § 137 Abs. 1 Satz 1 Nr. 2 SGB V für nach § 108 SGB V zugelassene Krankenhäuser. Fassung vom: 16.05.2006, letzte Änderung: 03.02.2016 BAnz AT 12.04.2016 B2. www.g-ba.de/informationen/richtlinien/47/
  6. Schröder HM, Lilienthal S, Schreiber-Gollwitzer BM, Griessmeier B, Leiss U. AWMF Leitline: Psychosoziale Versorgung in der Pädiatrischen Onkologie. Registernummer 025-002. www.awmf.org/leitlinien/detail/ll/025-002.html
  7. Graf N, Furtwängler R. Preoperative chemotherapy and local stage III in nephroblastoma. Transl Pediatr. 2014; 3(1):4-11. 
  8. Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res. 2015;21(8):1904-15. 
  9. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arztebl Int. 2012;109(40):652-8. 
  10. Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TW, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, Kirschner-Schwabe R. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2013;27(2):295-304.
  11. Niemeyer, C und Eggert, A (Hrsg). Pädiatrische Hämatologie und Onkologie, Springer Verlag 2016 (in Druck). 
  12. Ernestus K, Pietsch T, Gessler M, Simon T, Hero B, Berthold F. Structure, Use, and Risks of Biomaterial Repositories of Embryonal Tumors. Klin Padiatr 2006; 218(3): 132-138
  13. J. Fuchs (Editor). Solide Tumoren im Kindesalter. Kapitel 4.5: Chirurgische Therapie. Schattauer Verlag 2012. 
  14. Kortmann RD, Bongartz R, Dieckmann K, Dunst J, Flentje M, Gademann G, Christiansen H, Kamprad FH, Karstens JH, Pape H, Rühl U, Schmidt BF, Willich N, Schulz-Ertner D, Schwarz R, Timmermann B, Pohl F, Klingebiel T, Jürgens H, Rübe C. Requirements and performance profile of the Paediatric Radiation Oncology Working Group (APRO): evaluation of the present situation and description of future developments. Klin Padiatr. 2007; 219(3):166-72. 
  15. Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872-7. 
  16. Strotman LN, Millner LM, Valdes R Jr, Linder MW. Liquid Biopsies in Oncology and the Current Regulatory Landscape. Mol Diagn Ther. 2016;20(5):429-36. 
  17. von Stackelberg A, Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Copper TM, DuBois SG, O'Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L.  A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood 2013; 122:70;
  18. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin forneuroblastoma. N Engl J Med. 2010;363(14):1324-34. 
  19. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. 
  20. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-18. 
  21. Künkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, Chang CA, Rolczynski LS, Brown C, Mgebroff S, Berger M, Park JR, Jensen MC. Preclinical Assessment of CD171-Directed CAR T Cell Adoptive Therapy For Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility. Clin Cancer Res. 2016 Jul 7. pii: clincanres.0354.2016. 
  22. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wößmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016;65:91-101. 
  23. Stark DP, Vassal G (Hrsg). Tumors in Adolescents and Young Adults. Karger Verlag 2016. 
  24. Report of the Adolescent and Young Adult Oncology Progress Review Group, National Cancer Institute and the LIVESTRONG Young Adult Alliance, NIH Publication No. 06-6067, Bethesda, MD. www.cancer.gov/types/aya/research/ayao-august-2006.pdf
  25. Bleyer A, Viny A, Barr R. Epidemiology, Access, and Outcomes: SEER Series - Cancer in 15- to 29-Year-Olds by Primary Site. The Oncologist 2006; 11:590–601
  26. Langer T, Schuster S, Eggert A. Nachsorge nach onkologischen Erkrankungen. Monatsschrift Kinderheilkunde 2015; 163(2):112–119. 
  27. Robison LL, Hudson MM (2014) Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 14(1):61–70
  28. Langer T, Henze G, Beck JD (2000) Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol 34(5):348–351
  29. Langer T, Stöhr W, Paulides M et al (2005) Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr 217(3):176–181